Expertise
-
Practice Areas:
- Bar Admissions:
- Education:
- University of Calgary (2020) JD
- University of British Columbia (2015) MSc (Chemistry)
- Saint Mary's University (2012) BSc (Chemistry)
Details
- Bio
- Cases
- Associations
- Blog Posts
- News & Media
- Publications & Presentations
Amber Blair (she/her)
is an associate at Lenczner Slaght.
Amber's developing practice includes a broad range of intellectual property and commercial litigation. Amber has experience with disputes involving companies in the pharmaceuticals, biotechnology, life sciences, chemistry, telecommunications, technology, and oil and gas sectors.
Prior to joining Lenczner Slaght, Amber practiced in the intellectual property litigation group at a large international firm in Calgary and summered and articled at a leading national intellectual property boutique.
Before law school, Amber earned her BSc in chemistry from Saint Mary's University and her MSc in chemistry from the University of British Columbia. Amber's master’s research focused on designing innovative ways to increase the efficiency of dye-sensitized solar cells. After that, Amber worked as a chemistry instructor at Simon Fraser University and as a marketing specialist at a major Canadian biotechnology company.
-
Gilead Sciences, Inc et al v Pharmascience Inc
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
-
Gilead Sciences, Inc et al v Pharmascience Inc
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
-
Gilead Sciences, Inc et al v JAMP Pharma Corporation
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,990,210.
-
Gilead Sciences, Inc et al v Natco Pharma (Canada) Inc
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
-
Gilead Sciences Inc, et al v JAMP Pharma Corporation
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
-
Gilead Sciences, Inc et al v Apotex Inc
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
-
Gilead Sciences, Inc et al v Natco Pharma (Canada) Inc
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent Nos. 2,845,553 and 2,990,210.
-
Gilead Sciences, Inc et al v Apotex Inc
Counsel to Gilead Sciences, Inc. and Gilead Sciences Canada, Inc. in a NOC action in the Federal Court in respect of Canadian Patent No. 2,845,553.
-
Rovi Guides v BCE Inc, Ericsson et al
Counsel to Adeia Guides, Inc. and Adeia Media Holdings LLC in a patent infringement action involving four patents related to digital entertainment technologies.
-
Sunovion Pharmaceuticals Canada Inc et al v JAMP Pharma Corporation
Counsel to Sunovion in a NOC action relating to LATUDA (lurasidone), an antipsychotic medication used to treat bipolar disorder and schizophrenia. (Prior to joining Lenczner Slaght).
-
Law Society of Ontario
-
Ontario Bar Association
-
Shocking Result? Summary Trial on Battery Jump Starter Patent Fails to Get Going
Patent infringement cases are complex and technical, and historically Canadian courts were reluctant to endorse summary disposition in the patent context. However, in recent years there has been an increased trend towards the application of summary proceedings in this area. In particular, we have previously commented on decisions of the Federal Court (“FC”) (Canmar, Kobold, and Janssen) and Federal Court of Appeal (“FCA”) (Canmar and ViiV) that demonstrate the Court’s willingness to approve summary proceedings in patent cases under the appropriate circumstances. Last fall, the FCA decision in Gemak was interpreted by some commentators as a return to the historical position, but in our view, Gemak can be viewed as tapping the brakes on summary judgment rather than signalling a more sweeping reversal of the trend towards summary adjudication.
-
To Consolidate or Not to Consolidate – This is the Federal Court’s Question
In a recent decision, Takeda Canada Inc v Apotex Inc, the Federal Court dismissed the Plaintiff, Takeda’s, motion for consolidation of two actions against Apotex relating to Takeda’s dexlansoprazole (DEXILANT) under section 6 of the Patented Medicines (Notice of Compliance) Regulations (the “PM(NOC) Regulations”).
-
Lenczner Slaght Welcomes Seven New Associates
Canada’s leading litigation firm continues to add to its collective experience and knowledge with the addition of seven exceptional associates.
-
Amber Blair co-authored the article "Kinetics teach that electronic coupling lowers the free-energy change that accompanies electron transfer" which was published in the Proceedings of the National Academy of Sciences.
-
Crystal structure of 2-azido-1,3-bis(2,6-diisopropylphenyl)-1,3,2-diazaphospholidine
Amber Blair co-authored the article "Crystal structure of 2-azido-1,3-bis(2,6-diisopropylphenyl)-1,3,2-diazaphospholidine" which was published in Acta Crystallographica Section E.
-
Kinetic pathway for interfacial electron transfer from a semiconductor to a molecule
Amber Blair co-authored the article "Kinetic pathway for interfacial electron transfer from a semiconductor to a molecule" which was published in Nature Chemistry.
-
1-(2,4,6-Triisopropylphenyl)ethanone
Amber Blair co-authored the article "1-(2,4,6-Triisopropylphenyl)ethanone" which was published in Acta Crystallographica Section E.